ALNY Stock Recent News

Could Alnylam Pharmaceuticals (NASDAQ: ALNY ) become a household name in 2024? At the very least, the company should be well known in the medical community.

Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive.

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra.

Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.

CNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like.

HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and cardiovascular events, with positive results in secondary endpoints and a good safety profile. Results support the use of Amvuttra as monotherapy or in combination with stabilizers in people with ATTR-CM, potentially generating billions in incremental revenue for Alnylam.

Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition.

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug.  Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.

Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascular events in a study of patients with a rare heart disease.

Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra.